Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- WEBSITE NEWS
May 17, 2004
- Eli Lilly Japan Aims at \5 Bil. Sales with Evista in 1st Year
May 17, 2004
- Annual Business Results
May 17, 2004
- MPC New Management Determined to Take Off Toward a Global House
May 17, 2004
- 1st Qtr Business Results
May 17, 2004
- Mochida's New 3-Year Management Plan Announced
May 17, 2004
- IMSUT to Study Tailor-made Medicine with Iressa, Glivec
May 17, 2004
- Janssen's "Spend A Day" MR Support Program Found Effective
May 17, 2004
- The 48th Meeting of the Japan College of Rheumatology
May 17, 2004
- Alfresa Aims to Expand Group Membership in SAFE
May 17, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 17, 2004
- Takeda, Banyu Hired Over 200 New Graduates in April: PJ Survey
May 17, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 17, 2004
- Listed Wholesalers Increased Hiring of New Graduates: PJ Survey
May 17, 2004
- Annual Business Results
May 17, 2004
- Med Professionals Expect Latest Info on Quality, Efficacy, Safety from MRs: Survey
May 17, 2004
- 1st Qtr Business Results
May 17, 2004
- CPhI Japan 2004 Conference
May 17, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 17, 2004
- BUSINESS NEWS IN BRIEF
May 17, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…